Argus maintained its Hold rating on Novartis AG (ADR) (NYSE: NVS ) as it looks for a favorable entry point. However, the brokerage's long-term rating on the stock is Buy as many of the drugs under development ...
- Market Realist•2 days ago
AstraZeneca’s stock value has increased 11.9% over the last 12 months. Analysts estimate that it has the potential to return 17.8% over the next 12 months.
GlaxoSmithKline plc (GSK)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||43.04 x 100|
|Ask||44.65 x 400|
|Day's Range||43.65 - 44.10|
|52wk Range||37.24 - 45.58|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||2,733.75|
|Avg Vol (3m)||3,342,450|
|Dividend & Yield||2.20 (4.96%)|